Syngene International Ltd

Syngene Intl. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Syngene International Ltd

₹ 472 1.20%
19 May 3:21 p.m.
syngeneintl.com BSE: 539268 NSE: SYNGENE
About

Syngene (established in 1993) as a Biocon subsidiary is India's first Contract Research Organization (CRO) which expanded later to be an integrated service provider offering end-to-end drug discovery, development, and manufacturing services on a single platform (CRAMS). Total research & manufacturing infrastructure for the company is spread across 1.9 million square feet across locations. [1]

Key Points

Business Footprint:[1]
The company caters to diverse end-user industries like Pharmaceuticals, Animal Health, Agrochemicals, Consumer Packaged Goods, Chemicals/Polymers. It has 400+ active customers with engagements with 13 out of the top 15 global pharma companies. The company holds 400+ patents jointly with clients and has a base of 6000+ scientists.

Website BSE NSE
  • Market Cap ₹ 19,011 Cr.
  • Current Price ₹ 472
  • High / Low ₹ 729 / 380
  • Stock P/E 50.7
  • Book Value ₹ 120
  • Dividend Yield 0.27 %
  • ROCE 10.1 %
  • ROE 7.86 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company has reduced debt.
  • Company is almost debt free.

Cons

  • Stock is trading at 3.93 times its book value
  • The company has delivered a poor sales growth of 11.4% over past five years.
  • Company has a low return on equity of 10.4% over last 3 years.
  • Dividend payout has been low at 12.0% of profits over last 3 years

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Healthcare Services Healthcare Research, Analytics & Technology

Part of BSE 500 BSE Healthcare Nifty 500 Nifty500 Shariah Nifty Smallcap 100

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
994 808 910 854 917 790 891 944 1,018 874 911 917 1,036
680 596 656 622 600 620 646 660 674 668 711 708 733
Operating Profit 314 212 254 232 317 170 245 284 344 206 200 209 303
OPM % 32% 26% 28% 27% 35% 22% 27% 30% 34% 24% 22% 23% 29%
23 24 14 26 16 50 16 18 19 18 15 -55 16
Interest 10 10 13 11 13 12 13 12 16 12 13 12 12
Depreciation 96 102 105 108 111 107 111 109 106 111 116 114 112
Profit before tax 231 123 151 138 209 101 137 181 240 101 85 28 196
Tax % 23% 24% 23% 19% 10% 25% 23% 27% 24% 14% 21% 47% 25%
179 93 116 112 189 76 106 131 183 87 67 15 148
EPS in Rs 4.45 2.32 2.90 2.77 4.69 1.88 2.64 3.26 4.55 2.15 1.67 0.37 3.67
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
1,423 1,826 2,012 2,184 2,604 3,193 3,489 3,642 3,739
949 1,289 1,394 1,507 1,861 2,251 2,472 2,598 2,820
Operating Profit 474 537 618 678 743 942 1,017 1,045 918
OPM % 33% 29% 31% 31% 29% 30% 29% 29% 25%
53 75 153 94 75 63 77 101 -6
Interest 23 32 35 28 24 45 47 53 49
Depreciation 131 164 219 274 310 366 426 433 453
Profit before tax 372 415 517 469 484 594 621 660 411
Tax % 18% 20% 20% 14% 18% 22% 18% 25% 23%
305 332 412 405 396 464 510 496 317
EPS in Rs 7.64 8.29 10.30 10.12 9.88 11.57 12.69 12.33 7.86
Dividend Payout % 7% 3% 0% 0% 10% 11% 10% 10% 16%
Compounded Sales Growth
10 Years: %
5 Years: 11%
3 Years: 5%
TTM: 3%
Compounded Profit Growth
10 Years: %
5 Years: 0%
3 Years: -7%
TTM: -21%
Stock Price CAGR
10 Years: 9%
5 Years: -4%
3 Years: -13%
1 Year: -27%
Return on Equity
10 Years: %
5 Years: 11%
3 Years: 10%
Last Year: 8%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 200 200 400 400 401 401 402 402 403
Reserves 1,520 1,768 1,776 2,421 2,897 3,217 3,856 4,324 4,436
787 813 773 893 1,022 815 555 578 458
681 922 1,214 1,169 1,245 1,398 1,339 1,491 1,757
Total Liabilities 3,189 3,704 4,163 4,883 5,564 5,831 6,152 6,796 7,055
1,030 1,377 2,020 2,201 2,393 2,667 2,850 2,802 3,005
CWIP 155 274 234 237 346 177 838 1,266 1,040
Investments 158 716 776 702 1,034 918 548 647 741
1,846 1,337 1,133 1,743 1,790 2,069 1,916 2,081 2,268
Total Assets 3,189 3,704 4,163 4,883 5,564 5,831 6,152 6,796 7,055

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
446 630 677 701 581 824 1,042 1,168 915
-349 -646 -424 -629 -611 -653 -494 -744 -860
-79 -72 -226 58 -31 -342 -551 -142 -215
Net Cash Flow 18 -88 28 130 -62 -172 -4 281 -160
Free Cash Flow 82 47 34 255 105 305 553 398 547
CFO/OP 111% 135% 127% 116% 92% 102% 115% 123% 107%

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 68 68 72 79 71 61 46 53 50
Inventory Days 82 30 18 41 87 141 94 60 56
Days Payable 195 154 156 167 113 109 100 136 138
Cash Conversion Cycle -44 -56 -66 -47 45 92 40 -23 -32
Working Capital Days -48 -103 -172 -66 -43 -14 -27 -51 -24
ROCE % 17% 17% 14% 13% 15% 15% 14% 10%

Insights

In beta
Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Total Headcount
Number

Log in to view insights

Please log in to see hidden values.

Login
Laboratory and Infrastructure Area
Million sq. ft.
Number of Active Clients
Number
Number of Scientists
Number
Revenue Mix - Manufacturing (CDMO)
Percentage
Revenue Mix - Research Services (CRO)
Percentage
Patents held with clients
Number
Single-use Bioreactor Capacity (Large Molecules)
Litres

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

4 Recently
Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
54.80% 54.79% 54.79% 54.79% 54.72% 54.72% 52.74% 52.74% 52.68% 52.68% 52.68% 52.68%
23.19% 23.55% 21.20% 20.92% 20.64% 20.72% 20.65% 19.47% 16.51% 16.31% 14.96% 13.91%
11.20% 11.70% 14.63% 15.80% 16.78% 17.49% 19.52% 21.50% 24.05% 24.62% 25.83% 26.44%
10.23% 9.47% 9.07% 8.18% 7.44% 6.74% 6.79% 5.99% 6.45% 6.08% 6.22% 6.69%
0.60% 0.48% 0.32% 0.31% 0.43% 0.34% 0.29% 0.29% 0.31% 0.30% 0.29% 0.29%
No. of Shareholders 1,25,4551,25,9921,21,8801,15,8501,20,0181,07,3381,28,8061,25,0901,42,3101,36,0611,31,7501,35,605

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings

Concalls